Extended Data Fig. 7: AMG 510 inhibits KRAS(G12C) signalling and viability of syngeneic CT-26 KRASG12C cells.
From: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
a, b, Cellular activity of AMG 510 and the MEK inhibitor trametinib in CT-26 KRASG12C and parental CT-26 cell lines as measured by the inhibition of p-ERK after a 2-h treatment (a; mean ± s.d., n = 3 replicates; except trametinib in CT-26, mean of n = 2 replicates) and the effects on cell viability after 72-h treatment in spheroid culture (b; AMG 510 in CT-26 KRASG12C, mean ± s.d., n = 3 replicates; all others, mean of n = 2 replicates).
